Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 415.9 million
Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 415.9 million

December 15, 2022 Capital Markets and Public M&A Life Sciences & Health

Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.

Hansa Biopharma is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Petter Hellgren.

Related

Vinge advises Got Your Back on its acquisition of Nordic Depository Services' operations within depositary services for alternative investment funds

 Nordic Depositary Services provides depositary services for alternative investment funds with focus on real estate and renewable energies.
September 10, 2024

Vinge advises the sellers in conjunction with the sale of Keeros AB

Keeros AB is a fintech company that offers comprehensive solutions for invoicing, lending and leasing. The acquisition was made by Marathon Software AB which is an investment company niched towards software companies.
September 10, 2024

Vinge advises the sellers in conjunction with the sale of Konsert Strategy & IP AB

Konsert Strategy & IP AB, is a Swedish management consultancy company blending business strategy and intellectual property. The acquisition was made by Rouse International, a leading international firm offering intellectual property services.
September 10, 2024